BridgeBio Pharma, Inc.
BBIO Nasdaq
SEC CIK 1743881
Follow BridgeBio Pharma
Weekly email: filings, results
Revenue, last quarter
$353.2M
+192.6% vs same quarter last year
Net income
−$56.7M
+69% vs same quarter last year
EPS, diluted
−$0.42
+55.8% vs same quarter last year
Operating cash flow
−$44.2M
+59.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $502.1M | −$732.9M |
| FY24 | $221.9M | −$543.3M |
| FY23 | $9.3M | −$653.3M |
| FY22 | $77.6M | −$484.6M |
| FY21 | $69.7M | −$586.5M |
| FY20 | $8.2M | −$505.5M |
| FY19 | $40.6M | −$288.6M |
| FY18 | - | −$169.5M |
| FY17 | - | −$43.8M |
| FY16 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 95.8% | −104.2% | −146% |
| FY24 | 98.3% | −267.2% | −244.9% |
| FY23 | 73.7% | −6528.8% | −7021.9% |
| FY22 | 95.6% | −659.6% | −624.1% |
| FY21 | 95.5% | −827.1% | −841.2% |
| FY20 | - | −5752% | −6127.9% |
| FY19 | - | −656.4% | −711.5% |
| FY18 | - | - | - |
| FY17 | - | - | - |
| FY16 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$447M |
| FY24 | −$521.7M |
| FY23 | −$529M |
| FY22 | −$424.3M |
| FY21 | −$511.2M |
| FY20 | −$407.2M |
| FY19 | −$256.2M |
| FY18 | −$138.8M |
| FY17 | −$41M |
| FY16 | - |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | - | $48.3M |
| FY24 | - | $0 |
| FY23 | - | $0 |
| FY22 | - | $0 |
| FY21 | - | $200M |
| FY20 | - | $75M |
| FY19 | $997K | - |
| FY18 | - | - |
| FY17 | $1.2M | - |
| FY16 | - | - |
- BridgeBio Pharma
- Healthcare median
Show the numbers
| Year | BridgeBio Pharma | Healthcare median |
|---|---|---|
| FY25 | −146% | −30.6% |
| FY24 | −244.9% | −47% |
| FY23 | −7021.9% | −58% |
| FY22 | −624.1% | −80.4% |
| FY21 | −841.2% | −71.8% |
| FY20 | −6127.9% | −62.2% |
| FY19 | −711.5% | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |